KRAZATI® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson
Biologics by McKesson joined a limited distribution network for KRAZATI, approved for previously treated adults with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer.